articleTop 1% cited
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Oncology · 2017 · Vol. 18(9) · pp. 1274–1284
Éric Pujade-Lauraine✉(Université Paris Cité)Jonathan A. Ledermann(University College London)Frédèric Selle(Hôpital Tenon)Val Gebski(University of Sydney)Richard T. Penson(Massachusetts General Hospital)Amit M. Oza(Princess Margaret Cancer Centre)Jacob Korach(Sheba Medical Center)Tomasz Huzarski(Pomeranian Medical University)Andrés Poveda(Fundación Instituto Valenciano de Oncología)Sandro Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")Michael Friedländer(Prince of Wales Hospital)Nicoletta Colombo(European Institute of Oncology)Philipp Harter(Kliniken Essen-Mitte)Keiichi Fujiwara(Saitama Medical University)Isabelle Ray‐Coquard(Université Claude Bernard Lyon 1)Susana Banerjee(Royal Marsden NHS Foundation Trust)Joyce F. Liu(Dana-Farber Cancer Institute)Elizabeth Lowe(AstraZeneca (United States))Ralph Bloomfield(AstraZeneca (United Kingdom))Patricia Pautier(Institut Gustave Roussy)Jacob Korach(Sheba Medical Center)Tomasz Huzarski(Pomeranian Medical University)Tomasz Byrski(Pomeranian Medical University)Patricia Pautier(Institut Gustave Roussy)Michael Friedländer(Prince of Wales Hospital)Philipp Harter(Kliniken Essen-Mitte)Nicoletta Colombo(University of Milan)Sandro Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")Giovanni ScambiaMaria Ornella NicolettoFiona NusseyAndrew R. ClampRichard T. Penson(Massachusetts General Hospital)Amit M. Oza(Princess Margaret Cancer Centre)A. Poveda Velasco(Fundación Instituto Valenciano de Oncología)Manuel RodriguesJean‐Pierre LotzFrédèric Selle(Hôpital Tenon)Isabelle Ray‐Coquard(Université Claude Bernard Lyon 1)Diane ProvencherAleix Prat AparicioLaura Vidal Boixader(Université Paris Cité)Clare L. ScottKenji TamuraMayu YunokawaAlla LisyanskayaJacques MédioniNicolas PécuchetCoraline DubotThibault De La Motte RougeMarie‐Christine KaminskyB. WeberAlain LortholaryChristine ParkinsonJonathan A. Ledermann(University College London)Sarah WilliamsSusana Banerjee(Royal Marsden NHS Foundation Trust)Jonathan A. Cosin(University College London)James HoffmanRichard T. Penson(Massachusetts General Hospital)Marie PlanteAllan CovensGabe S. SonkeFlorence JolyAnne FloquetSusana Banerjee(Royal Marsden NHS Foundation Trust)Holger W. HirteAmnon Amit(Princess Margaret Cancer Centre)Tjoung-Won Park-SimonKoji MatsumotoSergei TjulandinJae‐Hoon Kim(Pomeranian Medical University)Laurence GladieffRoberto SabbatiniDavid M. O’MalleyPatrick TimminsDaniel KredentserNuria Laínez MilagroM.P. Barretina GinestaAriadna Tibau MartorellAlfonso Gómez de LiañoBelén Ojeda GonzálezLinda MileshkinMasaki MandaiIngrid BoerePetronella B. OttevangerJoo‐Hyun NamElias Abdo FilhoSalima HamiziFrancesco CognettiDavid WarshalElizabeth Dickson-Michelson(AstraZeneca (United States))Scott KamelleNathalie D. McKenzieGustavo C. RodriguezDeborah K. ArmstrongEva ChalasPaul CelanoKian BehbakhtSusan A. Davidson(Royal Marsden NHS Foundation Trust)Stephen WelchLimor HelpmanAmi Fishman(Princess Margaret Cancer Centre)Ilan BruchimMagdalena SikorskaAnna SłowińskaWojciech RogowskiMariusz BidzińskiBeata ŚpiewankiewiczAntonio CasadoCésar Mendiola FernándezMartina Gropp‐MeierToshiaki SaitoKazuhiro TakeharaTakayuki EnomotoHidemichi WatariChel Hun ChoiByoung‐Gie Kim(Pomeranian Medical University)Jae‐Weon Kim(Pomeranian Medical University)Roberto HeggIgnace Vergote
PARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentBRCA gene mutations in cancerOlaparibMedicineBRCA mutationOvarian cancerInternal medicineOncologyPlaceboPARP inhibitorClinical endpointPopulation
MeSH terms
Antineoplastic AgentsDouble-Blind MethodFemaleHumansMiddle AgedMutationOvarian NeoplasmsPhthalazinesPiperazinesTabletsGenes, BRCA1Genes, BRCA2Maintenance Chemotherapy
Funding
- European Society for Medical Oncology
Citations
1,842
FWCI
80.66
field-weighted impact
References
27
Percentile
100%
vs. same field & year
Citations per year
Cited by
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
CA A Cancer Journal for Clinicians · 2019 · 1,454 citations
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Annals of Oncology · 2019 · 1,130 citations
References
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
Gynecologic Oncology · 2015 · 310 citations
Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer
Gynecologic Oncology · 2011 · 417 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.